Myo-Inositol
2,000 mg per servingHow it works
Myo-inositol is the precursor to inositol phosphoglycan second messengers that sit downstream of the insulin receptor. When these messengers are depleted, cells respond poorly to insulin, the pancreas compensates with higher output, and elevated insulin stimulates ovarian theca cells to produce more testosterone. Restoring myo-inositol availability improves the efficiency of that signalling step, which is why androgen markers tend to move alongside insulin markers rather than independently.
Why this dose
2 g twice daily is the dose used across the majority of published metabolic and androgen-excess trials in women, most often paired with D-chiro-inositol in a physiological 40:1 ratio.
Selected research
Unfer et al., Gynecological Endocrinology (2017) — systematic review, 12 RCTs
Myo-inositol supplementation improved insulin sensitivity (HOMA-IR) and reduced circulating testosterone in women with insulin-driven androgen excess.
Nordio & Proietti, Eur Rev Med Pharmacol Sci (2012)
Combined myo/D-chiro-inositol improved metabolic and ovulatory parameters more than myo-inositol alone over 6 months.
Facchinetti et al., Trends Endocrinol Metab (2020) — expert consensus
Inositol described as a first-line, well-tolerated option for insulin-resistant women, with a safety profile comparable to placebo.
